# MariTide Dosing Guide: Once-Monthly 140–420 mg Phase 2 Map
> Note: PeptIQ is not a medical provider. MariTide (maridebart cafraglutide) is investigational. Doses below reflect published Phase 2 designs — not a consumer protocol.
MariTide is Amgen's long-acting peptide-antibody conjugate (formerly AMG 133), built for once-monthly (or less frequent) subcutaneous dosing. That monthly cadence is the SEO differentiator versus weekly tirzepatide / retatrutide calendars.
Quick Answer: MariTide Dosage
| Setting | Public Phase 2 anchors |
|---|---|
| Fixed monthly doses | 140 mg, 280 mg, 420 mg every 4 weeks |
| Less frequent arm | 420 mg every 8 weeks (no escalation) |
| Escalation arms | Climb to 420 mg every 4 weeks over 4-week or 12-week escalation |
| Route | Subcutaneous |
| Primary readout window | Weight change at week 52 |
What Phase 2 Showed
In the NEJM Phase 2 program (NCT05669599):
Obesity without T2D (efficacy-style public summaries): up to about ~20% mean weight loss at 52 weeks vs ~2–3% placebo, without a clear plateau.
Obesity with T2D: up to about ~17% mean weight loss, with HbA1c reductions up to roughly 2.2 percentage points in Amgen communications.
Treatment-policy / intention-to-treat style means in the NEJM report were somewhat lower (roughly low-to-mid teens % in the obesity cohort across active arms) — always check which estimand a headline uses.
Why Escalation Exists
GI adverse events were common. Public summaries note they were less frequent with dose escalation and lower starting doses. That is the same titration philosophy as weekly incretins — just on a monthly clock.
